Sandoz is “now beginning to stabilize” following a challenging start to 2021, with net sales increasing by 11% as reported and 5% in constant currencies to $2.397bn in the second quarter and core operating profit climbing by a tenth as reported to $520m.
Although parent Novartis continues to expect disruptions related to COVID-19 for Sandoz during 2021, “we do also expect healthcare systems...







